File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B
  • Basic View
  • Metadata View
  • XML View
TitleFailure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B
 
AuthorsChung, ML1
Chi, LL1
See, CC1
Lau, GK1
Sheung, TF1
 
KeywordsActive immunization
Antibody against hepatitis B surface antigen
Immunity
Recurrence
 
Issue Date2005
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
CitationJournal Of Hepatology, 2005, v. 43 n. 2, p. 283-287 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2005.03.013
 
AbstractBackground/Aims: Lamivudine prophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants. Methods: Fifty-two patients on lamivudine prophylaxis at a median of 412 days (median, 370-2040 days) after transplantation for chronic HBV-related liver disease received two courses of an accelerated schedule of double-dose recombinant HBV vaccine. Before vaccination, all patients were seronegative for HBsAg, anti-HBs and HBV DNA (by qPCR). Three intramuscular doses of vaccine (40 μg each) were administered monthly and another identical course was repeated after 3 months. Lamivudine (100 mg/day) was continued throughout the study. Results: After the first course, two patients developed a weak response (anti-HBs titre of 12 mIU/mL) that disappeared rapidly. One early responder developed anti-HBs (27 mIU/mL) again after the second course but the other did not. Two other patients developed response (anti-HBs titre of 17 and 103 mIU/mL, respectively) giving an overall response rate of 7.7%. The antibody level declined rapidly. At the end of the study, one patient who did not respond had developed viral breakthrough which was treated with adefovir dipivoxil therapy. Conclusions: Active immunization with two courses of double-dose recombinant HBV vaccine has limited efficacy in patients receiving lamividine prophylaxis after liver transplantation. © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
 
ISSN0168-8278
2012 Impact Factor: 9.858
2012 SCImago Journal Rankings: 2.797
 
DOIhttp://dx.doi.org/10.1016/j.jhep.2005.03.013
 
ISI Accession Number IDWOS:000230803900013
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorChung, ML
 
dc.contributor.authorChi, LL
 
dc.contributor.authorSee, CC
 
dc.contributor.authorLau, GK
 
dc.contributor.authorSheung, TF
 
dc.date.accessioned2010-09-06T08:39:02Z
 
dc.date.available2010-09-06T08:39:02Z
 
dc.date.issued2005
 
dc.description.abstractBackground/Aims: Lamivudine prophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants. Methods: Fifty-two patients on lamivudine prophylaxis at a median of 412 days (median, 370-2040 days) after transplantation for chronic HBV-related liver disease received two courses of an accelerated schedule of double-dose recombinant HBV vaccine. Before vaccination, all patients were seronegative for HBsAg, anti-HBs and HBV DNA (by qPCR). Three intramuscular doses of vaccine (40 μg each) were administered monthly and another identical course was repeated after 3 months. Lamivudine (100 mg/day) was continued throughout the study. Results: After the first course, two patients developed a weak response (anti-HBs titre of 12 mIU/mL) that disappeared rapidly. One early responder developed anti-HBs (27 mIU/mL) again after the second course but the other did not. Two other patients developed response (anti-HBs titre of 17 and 103 mIU/mL, respectively) giving an overall response rate of 7.7%. The antibody level declined rapidly. At the end of the study, one patient who did not respond had developed viral breakthrough which was treated with adefovir dipivoxil therapy. Conclusions: Active immunization with two courses of double-dose recombinant HBV vaccine has limited efficacy in patients receiving lamividine prophylaxis after liver transplantation. © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Hepatology, 2005, v. 43 n. 2, p. 283-287 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2005.03.013
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.jhep.2005.03.013
 
dc.identifier.epage287
 
dc.identifier.hkuros138679
 
dc.identifier.isiWOS:000230803900013
 
dc.identifier.issn0168-8278
2012 Impact Factor: 9.858
2012 SCImago Journal Rankings: 2.797
 
dc.identifier.issue2
 
dc.identifier.pmid15964658
 
dc.identifier.scopuseid_2-s2.0-21844435779
 
dc.identifier.spage283
 
dc.identifier.urihttp://hdl.handle.net/10722/83271
 
dc.identifier.volume43
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofJournal of Hepatology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Journal of Hepatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Hepatology, [VOL 43, ISSUE 2, 2005] DOI 10.1016/j.jhep.2005.03.013
 
dc.subject.meshHepatitis B Vaccines - administration and dosage - therapeutic use
 
dc.subject.meshHepatitis B virus - genetics - immunology
 
dc.subject.meshHepatitis B, Chronic - prevention and control - surgery - virology
 
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic use
 
dc.subject.meshVaccination
 
dc.subjectActive immunization
 
dc.subjectAntibody against hepatitis B surface antigen
 
dc.subjectImmunity
 
dc.subjectRecurrence
 
dc.titleFailure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chung, ML</contributor.author>
<contributor.author>Chi, LL</contributor.author>
<contributor.author>See, CC</contributor.author>
<contributor.author>Lau, GK</contributor.author>
<contributor.author>Sheung, TF</contributor.author>
<date.accessioned>2010-09-06T08:39:02Z</date.accessioned>
<date.available>2010-09-06T08:39:02Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>Journal Of Hepatology, 2005, v. 43 n. 2, p. 283-287</identifier.citation>
<identifier.issn>0168-8278</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/83271</identifier.uri>
<description.abstract>Background/Aims: Lamivudine prophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants. Methods: Fifty-two patients on lamivudine prophylaxis at a median of 412 days (median, 370-2040 days) after transplantation for chronic HBV-related liver disease received two courses of an accelerated schedule of double-dose recombinant HBV vaccine. Before vaccination, all patients were seronegative for HBsAg, anti-HBs and HBV DNA (by qPCR). Three intramuscular doses of vaccine (40 &#956;g each) were administered monthly and another identical course was repeated after 3 months. Lamivudine (100 mg/day) was continued throughout the study. Results: After the first course, two patients developed a weak response (anti-HBs titre of 12 mIU/mL) that disappeared rapidly. One early responder developed anti-HBs (27 mIU/mL) again after the second course but the other did not. Two other patients developed response (anti-HBs titre of 17 and 103 mIU/mL, respectively) giving an overall response rate of 7.7%. The antibody level declined rapidly. At the end of the study, one patient who did not respond had developed viral breakthrough which was treated with adefovir dipivoxil therapy. Conclusions: Active immunization with two courses of double-dose recombinant HBV vaccine has limited efficacy in patients receiving lamividine prophylaxis after liver transplantation. &#169; 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jhep</publisher>
<relation.ispartof>Journal of Hepatology</relation.ispartof>
<rights>NOTICE: this is the author&#8217;s version of a work that was accepted for publication in Journal of Hepatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Hepatology, [VOL 43, ISSUE 2, 2005] DOI 10.1016/j.jhep.2005.03.013</rights>
<subject>Active immunization</subject>
<subject>Antibody against hepatitis B surface antigen</subject>
<subject>Immunity</subject>
<subject>Recurrence</subject>
<subject.mesh>Hepatitis B Vaccines - administration and dosage - therapeutic use</subject.mesh>
<subject.mesh>Hepatitis B virus - genetics - immunology</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - prevention and control - surgery - virology</subject.mesh>
<subject.mesh>Reverse Transcriptase Inhibitors - therapeutic use</subject.mesh>
<subject.mesh>Vaccination</subject.mesh>
<title>Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.jhep.2005.03.013</identifier.doi>
<identifier.pmid>15964658</identifier.pmid>
<identifier.scopus>eid_2-s2.0-21844435779</identifier.scopus>
<identifier.hkuros>138679</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-21844435779&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>43</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>283</identifier.spage>
<identifier.epage>287</identifier.epage>
<identifier.isi>WOS:000230803900013</identifier.isi>
<publisher.place>Netherlands</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong